Hungarian firms negotiating with Azerbaijani manufacturers in pharma sector

Hungarian companies are conducting negotiations with local manufacturers to establish long-term partnerships in the pharmaceutical sector in Azerbaijan and declare that no compromises are made on the quality of pharmaceutical preparations, József Péter Pallos, Chief Executive Officer of PannonPharma Ltd., told Report.

Pallos noted that pharmaceuticals, medical devices, vaccines, bioprocessing, stem cell treatment, organ transplantation, medical diagnostics, assisted reproduction, transfusion blood processing, biosafety levels/3/4/5, etc., the same quality system framework principle be obeyed to.

“Quality is uncompromised, patients are first. But don't forget, any regulation is worth as much as it is respected. The National regulatory bodies of the government have a high responsibility for the safety of the population, and shall be staffed at the highest level, accordingly. Don't forget the recent tragedy in the neighborhood, the dozen fatal cases of kids, caused by toxic medicine from India. Beyond the control, national regulatory offices have the unique capability to set the technology level as high as necessary. Tremendous knowledge is collected by regulatory officers, simply by evaluating pharmaceutical documentation submitted for product registration of pharmaceutical companies. Responsible governance means also, strategic mindset. None of the developed countries can afford the supply-chain of medicines to be broken in case of any emergency situation, national pharmaceutical industry able to deliver life-saving basic preparations is a must,” he said.

The CEO noted that the company's main goal is to enter the Azerbaijani market by collaborating with local partners:

“We might be a partner in setting up quality assurance management, and operation systems in pharma/health industries in their strategic planning, business development, R&D, manufacturing, data management, Artificial Intelligence (AI) deployment, distribution and logistics, pharmacovigilance, etc.

We arrive to Baku with the proposal for joint activities, in industry - production system development; academy - education aspects for pharma/health professionals; fostering academic R&D especially in drug discovery phase based on medicinal herbs; governmental - regulatory support for developing high tech pharma/health entities; and business development - offering our unique medicines, looking for local products.”

Csaba Pacz, Chief Commercial Officer of Egis Pharmaceuticals Plc told Report that they prioritize the development of mutually beneficial cooperation with local producers in Azerbaijan, aiming to promote strong, long-term partnerships that will drive sustainable development in the industry:

“EGIS is dedicated to providing high quality healthcare solutions and enhancing the well-being of the people in Azerbaijan. Our primary focus lies in key therapeutic areas such as cardiology, the central nervous system, and consumer healthcare. We are dedicated to addressing the unique healthcare needs of the community through these specialized fields. Our strategy includes not only the introduction of new products but also the establishment of potential long-term partnerships with local manufacturers. These collaborations will be centered around our core therapeutic areas, ensuring that we continue to support for the health and wellness of the population.”

András Orosz, Region Head of Gedeon Richter Plc, told Report that they have representative offices in Baku responsible for the promotion of innovative and generic products:

“We have a representative office in Baku, which is responsible for promotional activity of our innovative and generic products. We have a wide portfolio of products in different therapeutic areas, we are offering a big number of essential drugs. We are a leading company in women's healthcare in Azerbaijan. Our firm aims to introduce plenty of new products within 3-4 years, not only generics but innovative as well, so this market is really important for us in order to deliver our goals in GENMED (generic products), Women Healthcare, and CNS (central and nervous system) pillars.”